Expression of concern: Efficacy of sorafenib after liver transplantation in patients with primary hepatic carcinoma exceeding the Milan criteria: A preliminary study (Onco Targets Ther., (2012) 5, (457-462), 10.2147/OTT.S31387);Efficacy of sorafenib after liver transplantation in patients with primary hepatic carcinoma exceeding the Milan criteria: A preliminary study

OncoTargets and Therapy

Volumn 5, Issue , 2012, Pages 457-462

  Huang, Lei ^a   Li, Guang Ming ^a   Zhu, Ji Ye ^a   Li, Zhao ^a   Li, Tao ^a   Leng, Xi Sheng ^a  

^a PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

Author keywords

Chemotherapy; Follow up; Recurrence; Side effect; Survival rate; Targeted therapy

Indexed keywords

CAPECITABINE; HEPATITIS B ANTIBODY; LAMIVUDINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; SORAFENIB; TACROLIMUS;

ADULT; ALOPECIA; ANOREXIA; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG WITHDRAWAL; FATIGUE; FEMALE; HAND FOOT SYNDROME; HEPATITIS B; HUMAN; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; LIVER CELL CARCINOMA; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; LUNG METASTASIS; LYMPH NODE METASTASIS; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; POSTOPERATIVE PERIOD; RANDOMIZED CONTROLLED TRIAL; REVIEW; SURVIVAL RATE; SURVIVAL TIME; TREATMENT DURATION; TREATMENT OUTCOME; TUMOR RECURRENCE; WEAKNESS;

EID: 84873888518     PISSN: 11786930     EISSN: 11786930     Source Type: Journal    
DOI: 10.2147/OTT.S257418     Document Type: Erratum

References (13)

1. Mazzaferro V, Llovet JM, Miceli R, et al. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol. 2009; 10:35-43.
2. Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004;64:7099-7109.
3. Chang YS, Adnane J, Trail PA, et al. Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models. Cancer Chemother Pharmacol. 2007; 59:561-574.
4. Thomas M. Molecular targeted therapy for hepatocellular carcinoma. J Gastroenterol. 2009;44:136-141.
5. Dallago L, Dhondt V, Awada A. Selected combination therapy with sorafenib a review of clinical data and perspectives in advanced solid tumors. Oncologist. 2008;13:845-848.
6. Kelley RK, Venook A P. Sorafenib in hepatocellular carcinoma: separating the hype from the hope. J Clin Oncol. 2008;26:5845-5848.
7. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378-390.
8. Rimassal L, Santoro A. Sorafenib therapy in advanced hepatocellular carcinoma: the SHARP trial. Expert Rev Anticancer Ther. 2009;9: 739-745.
9. Llovet JM, Bruix J. Molecular targeted therapies in hepatocellular carcinoma. Hepatolog y. 2008;48:1312-1327.
10. Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma a Phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10:25-34.
11. Saab S, McTigue M, Finn RS, et al. Sorafenib as adjuvant therapy for high-risk hepatocellular carcinoma in liver transplant recipients: feasibility and Efficacy. Exp Clin Transplant. 2010,8:307-313.
12. Saidi RF, Shah SA, Rawson A P, et al. Treating hepatocellular carcinoma with sorafenib in liver transplant patients: an initial experience. Transplant Proc. 2010;42:4582-4584.
13. Huang L, Zhu JY, Li GM, et al. Postoperative recurrence of liver malignant tumor after liver transplantation. Chinese Journal of General Surgery. 2009;24:984-987.